Healy J C, Frankforter S A, Graves B K, Reddy R L, Beck J R
Department of Pathology, Creighton University School of Medicine, Omaha, Neb.
Arch Pathol Lab Med. 1994 Apr;118(4):465-70.
Preoperative autologous blood donation is employed with increasing frequency, particularly in patients undergoing elective orthopedic procedures. While autologous transfusion decreases the incidence of postoperative infections and other complications, the cost-effectiveness of this therapy has not been fully investigated. We constructed a decision analytic model to study the cost-effectiveness of preoperative autologous blood donation of packed red blood cells compared with allogeneic packed red blood cells in primary hip arthroplasty. We used data from 73 patients presenting at our blood center with a prescription for 2 U of autologous red blood cells prior to hip arthroplasty to establish probabilities for the number of units that would be donated. Patients were able to donate an average of 1.9 U (range, 0 to 2 U) of autologous blood. We also reviewed the charts of 56 patients who underwent primary hip arthroplasty to model the number of units given during hospitalization (1.5 U given; range, 0 to 5 U). We applied the model to a 65-year-old patient undergoing primary hip arthroplasty. Estimates for the incidence of posttransfusion hepatitis, chronic active hepatitis, human immunodeficiency virus infection, postoperative bacterial infection, and fatal hemolytic transfusion reaction were derived from the literature. Patient utility was measured in life-years. Costs included the cost of preoperative autologous blood donation, blood administration, and medical care costs associated with the complications of transfusion. Costs were derived from local data and the literature. Future earnings lost were not modeled. In the baseline analysis, autologous transfusion results in a net cost savings compared with allogeneic blood over a wide range of complication rates, patient ages, and transfusion requirements. The dominant factor in the analysis is the effect of postoperative bacterial infection on length of hospital stay and the resultant increase in costs. The effect of viral infections on the results of the analysis is minimal.
术前自体血捐献的应用频率日益增加,尤其是在接受择期骨科手术的患者中。虽然自体输血可降低术后感染及其他并发症的发生率,但该疗法的成本效益尚未得到充分研究。我们构建了一个决策分析模型,以研究在初次髋关节置换术中,与异体浓缩红细胞相比,术前自体浓缩红细胞输血的成本效益。我们使用了来自73名在我们血液中心就诊的患者的数据,这些患者在髋关节置换术前有2单位自体红细胞的处方,以确定可能捐献的单位数量的概率。患者平均能够捐献1.9单位(范围为0至2单位)的自体血。我们还查阅了56例接受初次髋关节置换术患者的病历,以模拟住院期间输注的单位数量(输注1.5单位;范围为0至5单位)。我们将该模型应用于一名65岁接受初次髋关节置换术的患者。输血后肝炎、慢性活动性肝炎、人类免疫缺陷病毒感染、术后细菌感染和致命性溶血性输血反应的发生率估计值来自文献。患者效用以生命年衡量。成本包括术前自体血捐献的成本、输血成本以及与输血并发症相关的医疗护理成本。成本来自当地数据和文献。未对未来收入损失进行建模。在基线分析中,与异体输血相比,在广泛的并发症发生率、患者年龄和输血需求范围内,自体输血可实现净成本节约。分析中的主要因素是术后细菌感染对住院时间的影响以及由此导致的成本增加。病毒感染对分析结果的影响最小。